Zelepar
Drug - Zelepar (selegiline) rapidly disintegrating tablets 1.25 mg
October 2007
| Description |
An irreversible MOA-B inhibitor intended for oral mucosal absorption |
| Dose |
1.25 mg QD x 6 weeks, then 2.5 mg QD |
| AWP |
$4.67/tab |
Zelepar criteria
- Patient has Parkinson’s disease AND
- Patient is on levodopa/carbidopa and is experiencing significant “off” periods or a deterioration in the quality of their response to therapy AND
- Patient has tried a 5mg dose of oral selegiline tablets or capsules but has had therapeutic failure due to adverse events
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411
